What side effects are associated with this type of intervention?

The most common treatments for bronchiolitis include supportive care, bronchodilators, and corticosteroids. Supportive care, such as hydration and oxygen therapy, generally has minimal side effects but may include nasal irritation from oxygen delivery. Bronchodilators, like albuterol, can cause side effects such as increased heart rate, jitteriness, and tremors. Corticosteroids, though less commonly used, can lead to side effects like increased appetite, mood changes, and elevated blood pressure. It is important to consult with a healthcare provider to tailor the treatment plan to the individual patient's needs.

What prior FDA approvals exist?

There are no specific FDA-approved drugs mentioned in the provided context for the treatment of bronchiolitis. The multi-condition clinical pathway intervention being studied focuses on standardizing and promoting evidence-based practices for managing asthma, pneumonia, and bronchiolitis in hospitalized children. This approach likely includes supportive care measures such as oxygen therapy, hydration, and possibly the use of bronchodilators or corticosteroids, which are commonly used in the management of these respiratory conditions.

What other types of research exist?

Promising alternatives to the Multi-condition Clinical Pathway Intervention for bronchiolitis patients in 2024 include: 1) High-flow nasal cannula (HFNC) therapy, which has shown effectiveness in reducing respiratory distress and the need for mechanical ventilation. 2) The use of nebulized hypertonic saline, which can improve mucociliary clearance and reduce hospital stay duration. 3) Implementation of telemedicine for remote monitoring and management, allowing for timely interventions and reducing hospital visits. 4) Enhanced vaccination strategies, including the use of monoclonal antibodies like palivizumab, to prevent severe respiratory syncytial virus (RSV) infections, a common cause of bronchiolitis.

← Back to Search

Clinical Pathway Intervention for Pediatric Respiratory Conditions (SIP Trial)

N/A

Recruiting

Led By Sunitha V Kaiser, MD, MSc

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Primary diagnosis of asthma AND age >2 to <18 years-old at time of admission to the hospital

Primary diagnosis of pneumonia AND age >2 months and <18 years at time of admission to the hospital

Must not have

Diagnosis of SARS-CoV-2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30 days after hospital discharge

Awards & highlights

No Placebo-Only Group

Summary

This trial tests a new way to help doctors treat children with asthma, pneumonia, or bronchiolitis in community hospitals. The method uses simple visual guides to ensure doctors follow the best care practices. The goal is to improve health outcomes and reduce hospital stays and costs.

Who is the study for?

This trial is for children hospitalized with asthma (ages 2-18), pneumonia (ages 2 months to <18 years), or bronchiolitis (<2 years old) in community hospitals. It excludes those with COVID-19, chronic illnesses like lung or heart disease, neurologic disorders, or transfers from other inpatient facilities.

What is being tested?

The study tests a multi-condition clinical pathway intervention aimed at increasing clinicians' use of evidence-based practices for treating asthma, pneumonia, and bronchiolitis over two years. The trial randomly assigns hospitals to either the new pathway or control group.

What are the potential side effects?

Since this trial focuses on implementing care pathways rather than direct medical treatments, it does not have traditional side effects. However, there may be indirect impacts on patient care outcomes such as length of stay and readmission rates.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have asthma and am between 2 and 18 years old.

Select...

I was diagnosed with pneumonia and am between 2 months and 18 years old.

Select...

My child was diagnosed with bronchiolitis and is under 2 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have been diagnosed with COVID-19.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 days after hospital discharge

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 days after hospital discharge

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days after hospital discharge for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Asthma Evidence Based Practice 1

Asthma Evidence Based Practice 2

Asthma Evidence Based Practice 3

+4 more

Secondary study objectives

30-day Hospital Readmission or Emergency Department Revisit

Length of Hospital Stay

Transfer to Intensive Care

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Multi-condition Pathway InterventionExperimental Treatment1 Intervention

The multi-condition pathway intervention consists of pathways clinicians select from to guide the care of children with asthma, pneumonia, or bronchiolitis. Key implementation strategies include audit and feedback, plan-do-study-act cycles, and electronic order sets.

Group II: Standard of CareActive Control1 Intervention

Hospitals randomized to the control arm will not receive the multi-condition pathway intervention or any external supports for implementation. They will continue to provide current standards of care.

0 / 4Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for bronchiolitis include supportive care measures such as hydration, oxygen therapy, and suctioning of nasal secretions. These treatments work by ensuring the patient maintains adequate oxygen levels and clear airways, which are crucial for breathing. In some cases, bronchodilators like albuterol may be used to relieve bronchospasm, although their efficacy is variable. The emphasis on these treatments in the Multi-condition Clinical Pathway Intervention is important because they standardize care and promote evidence-based practices, ensuring that patients receive the most effective and appropriate management for their condition.